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Background: Increased chronic therapy use and improved cystic ﬁbrosis (CF) patient health should be accompanied by reduced pulmonary exacerbation-
associated antibiotic treatment incidence.
Methods: Treatment incidence rates and associated sign/symptom scores from 1995–2005were studied in Epidemiologic Study of CF patients by route
(±IV) and age (b6, 6–12, 13–17, ≥18 years).
Results: Overall treatment incidence rate fell 0.0165 events/patient-year/year (P=.006); IV incidence fell 0.0179 (Pb .001). Non-IV incidence increased in
children ≤12 years (P≤ .002) while signiﬁcantly decreasing in older patients. Mean IV (P=.046) and non-IV (P=.004) treatment-associated clinical
scores decreased in children b6 years. Non-IV (but not IV) clinical scores decreased in older patients.
Conclusions: IV incidence fell for all ages from 1995–2005; non-IV incidence increased in patients ≤12 years and fell in others. Average clinical
treatment thresholds fell in children b6 years; IV thresholds were unchanged in older patients; non-IV thresholds fell for patients≥13 years. Decreases
in treatment incidence were likely partially offset by lower treatment thresholds.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Pulmonary exacerbation; Epidemiology; Treatment thresholds1. Introduction
Pulmonary exacerbations (PEx) present unique challenges to
persons with cystic fibrosis (CF), their caregivers, CF drug
developers, and regulators. Although PEx are resource-intensive
events [1] that reduce patient quality of life [2–4], are associated
with morbidity [5], contribute to lung disease progression [6], and
are associated with reduced survival [7–9], a consensus prospec-
tive definition of PEx remains elusive [5]. In the absence of an⁎ Corresponding author at: 12520 33rd Street Ct E, Edgewood, WA 98372,
United States. Tel.: +1 253 370 5859.
E-mail address: enigmaster@comcast.net (D.R. VanDevanter).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2012.11.011accepted prospective definition, CF epidemiologists and drug
developers have employed a surrogate indicator of PEx: antibiotic
treatment in response to acute changes in respiratory signs and
symptoms. Although this pragmatic approach has allowed
estimation of the incidence of and risk factors associated with
antibiotic treatment for PEx [10,11] and treatment-associated
outcomes [6,12], it has important shortcomings. Clinician
thresholds for prescribing antibiotic treatment may differ [13],
possibly as a result of experience and management style. Thus, a
given patient history and clinical presentation may precipitate
antibiotic treatment (and thus be considered a PEx) in one setting
but not in another.
Despite variability associated with antibiotic treatment as a
surrogate measure for PEx, investigators have demonstratedby Elsevier B.V. All rights reserved.
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surface liquid hydrators [16,17], inhaled antibiotics [18–20],
macrolides [21–23], and CFTR potentiators [24,25] significantly
increase the time to and/or reduce the need for antibiotic
treatment of respiratory symptoms associated with PEx. As the
benefits of these therapies have been characterized, their use has
increased [26] and become incorporated into “standards” of
chronic CF respiratory care [27,28]. During the same period, the
overall health of the CF population has increased [29], which in
turn would be expected to be reflected in a noticeable reduction
in the incidence of antibiotic treatment for PEx over time.
Interestingly, there has been little evidence that antibiotic
treatment incidence for PEx has appreciably changed over past
decades [30], suggesting either that chronic CF therapies and
improved overall health are less effective at reducing PEx than
may have been previously believed, or that thresholds at which
CF clinicians intervene to treat increased respiratory signs and
symptoms have evolved over time, or both.
We have studied the demographics of PEx-associated
treatments in the Epidemiologic Study of Cystic Fibrosis (ESCF)
[31] from 1995 through 2005. PEx-associated antibiotic treatments
stratified by route of administration (intravenous [IV] versus
non-IV) were analyzed to characterize year-to-year changes in
incidence rates during the period.When available, acute changes in
clinical signs and symptoms of age-specific variables shown to be
associated with PEx treatment [32] were tabulated to estimate
clinical thresholds for antibiotic intervention over the period.
2. Methods
Patient encounters recorded in ESCF in which health
professionals administered antibiotics and reported that theseTable 1
Algorithm for scoring changes in clinical characteristics between most recent previ
encounter.
Clinical characteristic Raw value at encounters Condition indicating cha
New crackles 0=no [PEx]− [stable]=1
1=yes
Increased cough 0=none [PEx]− [stable]N0
1=occasionally
2=daily
Increased sputum 0=none [PEx]− [stable]N0
1=occasionally
2=daily
WFA decline 0–100
(percentile)
([PEx]− [stable]) / [stabl
FEV1 decline 10–150
(% predicted)
([PEx]− [stable]) / [Stab
New P. aeruginosa 0=negative [PEx] b− [stable] c=1
1=positive
Presence of hemoptysis 0=none [PEx]N0
1=scant
2=sub massive
3=massive
a Age group(s) for which individual scoring algorithms were applied, based on R
(noted by “X”), producing a modified Rabin score ranging from 0 to 4 changes from
b Any culture result within 2 weeks prior to and including PEx encounter.
c All culture results in the year (excluding the last 2 weeks) prior to PEx encounttreatments were specifically intended for the management of a
physician-identified PEx were studied. Antibiotic treatments that
were not administered for the management of what the treating
physician considered to be a PEx were excluded. Documentation
of patient age, sex, and date of ESCF enrollment was required for
study inclusion. Antibiotic treatment events were stratified as being
either IV treatments (where IV antibiotics were administered at
some point during treatment) or non-IV treatments (where no IV
antibiotics were administered over the course of treatment).
Physician-identified PEx (hereafter referred to simply as PEx)
treatment events were also stratified by the calendar year in which
they occurred (1995–2005) and the patient's age group on
December 31st of that year (b6, 6–12, 13–17, and ≥18 years of
age). The incidence rates of antibiotic treatment events associated
with PEx in each year and age subgroup were calculated by
dividing the number of observed PEx treatment events by the total
number of patient-years followed in ESCF for each age subgroup
each year.
When data were available, scores ranging from 0 to 4
representing changes in clinical signs and symptoms associated
with PEx treatment encounters were determined using a
modification of the system originally described by Rabin et al.
[32] (Table 1). For each age group, four age-specific clinical
parameters previously shown to be associated with PEx antibiotic
treatment [32] were assessed at the antibiotic treatment encounter
and at the patient's most recent previous stable encounter. A
modified Rabin score of 0 indicated no changes in clinical
parameters from the previous stable encounter, whereas a score of
4 indicated a worsening in all four age group-specific parameters
from the previous encounter. Description of raw parameter values
and algorithms for identifying change from previous stable
encounters to PEx encounters are shown in Table 1. Averageous (stable) encounter and pulmonary exacerbations (PEx) antibiotic treatment
nge from stable to PEx encounters Relevant age groups, years a
b6 6–12 13–17 18+
X X X X
X X X X
X
e]≤−0.45 X
le]≤−0.15 X X X
X
X X
abin et al. [31]. Four measures of clinical change are applied to each age group
immediate stable encounter.
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Fig. 1. Average annual incidence of antibiotic treatment events associated with
pulmonary exacerbations from 1995–2005 by administration route and age group.
Panel A, average incidence of all antibiotic treatment events. Panel B, incidence of
antibiotic treatment events not including IV antibiotics. Panel C, incidence of
antibiotic treatment events in which IV antibiotics were included. Open circles with
gray dashed lines, patients less than 6 years of age. Light gray circles with black
dashed lines, patients 6 to 12 years of age. Dark gray circles with solid gray line,
patients 13 to 17 years of age. Black circles with black lines, patients 18 years of age
and older. Note that vertical axes for Panels B and C differ from that of Panel A.
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were calculated for age and treatment type subgroups for each
calendar year.
Changes in the incidence of antibiotic treatment for PEx (as
treatment events per patient-year) and mean modified Rabin
scores associated with treatment over the study period were
assessed by simple linear regression. Proportions of year-to-year
variance in treatment incidence and mean modified Rabin scores
explained by time (R2) and associated P values for nonzero
regression slopes were calculated. All analyses were conducted
using SAS 9.2 (SAS Institute, Inc., Cary, NC).
3. Results
A total of 209,056 PEx-associated antibiotic treatments were
recorded over 186,273 ESCF patient-years studied between 1995
and 2005, resulting in an average incidence of 1.12 antibiotic
treatment events per patient-year. Of these, 102,689 (49.1%) were
non-IV antibiotic treatments and 106,367 (50.9%) were IV
treatments, corresponding to treatment incidences of 0.55/patient-
year and 0.57/patient-year, respectively. Overall antibiotic treat-
ment incidence decreased over the study period (slope=−0.0165
events per patient-year/year, R2 =0.58; P=.006), with this change
largely accounted for by a reduction in IV (slope=−0.0179,
R2 =0.77; Pb .001) but not in non-IV treatment incidence
(slope=+0.0014, R2 =0.03; P= .710).
Marked differences by age group were observed in antibiotic
treatment incidence over the study period (Fig. 1). Initially,
antibiotic treatment incidence roughly correlated with age group,
with adult treatment incidence approximately 3 times higher than
that of patients less than 6 years of age and intermediate treatment
incidence for patients of intermediate age. Over the study period,
adult treatment incidence steadily fell (slope=−0.0628, R2=0.86,
Pb .001), as did treatment incidence in 13- to 17-year-olds
(slope=−0.0348, R2=0.75, Pb .001), while treatment incidence
in children less than 6 increased (slope=+0.0290, R2 =0.62,
P= .004) and was essentially unchanged in 6- to 12-year-olds
(slope=+0.0049, R2 =0.16, P= .220) (Fig. 1A). By the end of
the observation period, overall antibiotic treatment incidence
was similar across age groups.
Changes over time in antibiotic treatment incidence differed by
antibiotic delivery route (IV versus non-IV) (Fig. 1B and C). IV
antibiotic treatment incidence consistently fell for all age groups
across the period (Fig. 1C and Table 2), while non-IV treatment
incidence increased in younger patients and fell in older patients
(Fig. 1B and Table 2). Although the rates at which treatment
incidence was observed to change over the period were not large,
all were statistically and significantly different from zero (Table 2).
Only 14.5% (30,357) of the 209,056 antibiotic treatment
events studied had sufficient accompanying data to be evaluable
by the modified Rabin clinical scoring algorithm (Table 1).
Events occurring in children less than 6 years old were most
likely to be evaluable, with an average of 27.0% of events being
evaluable per year, while events in 6–12 year olds were least
likely to be evaluable, with an average of 10.6% evaluable events
per year. With two exceptions (events in 1995 for patients 6 to
12 years of age and in 1997 for patients 13 to 17 years of age),meanmodified Rabin scores were always higher for IV compared
to non-IV interventions each year in every age group. This
difference at the population level is reflected in mean differences
between IV and non-IV scores across the study period for each
age group (Fig. 2A). Although associated clinical scores were
higher on average for patients treated with IV antibiotics than for
those not treated with IV antibiotics, clinical scores were not
predictive of antibiotic administration route, as 71.0% of patients
treated with IV antibiotics had associated Rabin scores of 0 or 1,
compared with 76.6% of patients treated with non-IV antibiotics
(Fig. 2B). Similarly, 4.6% of patients treated with non-IV
antibiotics had associated clinical scores of 3 or 4, compared with
7.3% of those whose treatment included IV antibiotics.
Table 3
Changes in mean modified Rabin clinical scores associated with evaluable
antibiotic treatment events by age group and route of administration, 1995–2005.
Slope, Rabin score/year (SE a) R2 P value b
Non-IV antibiotic treatment events
b6 −0.0207 (0.0054) 0.62 .004
6–12 −0.0129 (0.0058) 0.35 .054
13–17 −0.0111 (0.0036) 0.51 .014
≥18 −0.0092 (0.0018) 0.75 b .001
IV antibiotic treatment events
b6 −0.0268 (0.0116) 0.37 .046
6–12 0.0050 (0.0090) 0.03 .590
13–17 −0.0029 (0.0087) 0.01 .740
≥18 −0.0022 (0.0034) 0.05 .530
a Standard error.
b Test for nonzero slope.
Table 2
Changes in pulmonary exacerbations antibiotic treatment event incidence by
age group and route of administration, 1995–2005.
Slope, events/patient-year/year (SE a) R2 P value b
Non-IV antibiotic treatment events
b6 0.0376 (0.0080) 0.71 .001
6–12 0.0133 (0.0032) 0.67 .002
13–17 −0.0094 (0.0038) 0.41 .034
≥18 −0.0256 (0.0044) 0.79 b .001
IV antibiotic treatment events
b6 −0.0086 (0.0013) 0.83 b .001
6–12 −0.0084 (0.0020) 0.67 .002
13–17 −0.0253 (0.0040) 0.82 b .001
≥18 −0.0372 (0.0044) 0.89 b .001
a Standard error.
b Test for nonzero slope.
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associated with both non-IV antibiotic treatments and IV
treatments decreased significantly (P= .004 and P= .046,
respectively) for children less than 6 years of age (Table 3).
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Fig. 2. Distributions of modified Rabin scores and mean annual differences in mean
modified Rabin scores for evaluable IV and non-IV treatment events by age group.
Clear bars, antibiotic treatments not including IV antibiotics. Black bars, treatments
including IV antibiotics. Panel A, mean modified Rabin clinical scores associated
with pulmonary exacerbation treatment events between 1995 and 2005 by route of
administration and age group. Possible scores range from 0 to 4. Bars show 95%
confidence intervals for means. Panel B, distributions of treatment-associated
modified Rabin scores between 1995 and 2005 by route of administration.were also observed in older patients across the observation
period, reaching statistical significance in 13- to 17-year-olds
(P=.014) and adults (Pb .001), but not children 6 to 12 years of
age (P=.054) (Table 3). In contrast, no consistent trends were
observed in clinical score changes associated with IV antibiotic
treatments in patients 6 years of age and older (Fig. 3).IV Treatments
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Fig. 3. Average modified Rabin clinical scores associated with pulmonary
exacerbations from 1995–2005 by antibiotic administration route and age
group. Panel A, modified Rabin scores associated with antibiotic treatment events
not including IV antibiotics. Panel B, modified Rabin scores associated with
antibiotic treatment events in which IV antibiotics were included. Open circles
with gray dashed lines, patients less than 6 years of age. Light gray circles with
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line, patients 13 to 17 years of age. Black circles with black lines, patients 18 years
of age and older.
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Over recent decades, the intensity with which CF patients have
been treated with chronic respiratory therapies shown to reduce
risk of antibiotic treatment for PEx has markedly increased [26].
Over this same period, mean and median population measures for
factors associated with antibiotic treatment for PEx, including
pulmonary function and weight-for-age and respiratory signs and
symptoms [5,11], have steadily improved [29,30]. A logical
conclusion from these two observations would be that the
incidence of antibiotic treatment for PEx in the population should
have decreased during the period. However, such a conclusion
includes an assumption that clinician behavior regarding PEx
diagnosis and antibiotic intervention have not changed over time.
Our results suggest that there had, in fact, been a detectable
reduction in the incidence of treatment with IV antibiotics for PEx
between 1995 and 2005 across the CF population, but that this
reduction wasmore nuanced thanmight have been expected, being
more pronounced in older patients than in younger ones (Fig. 1C
and Table 2). Further, the incidence of antibiotic treatments that
did not include IV antibiotics actually increased significantly in
CF patients less than 12 years of age while decreasing significantly
in older patients over the period (Table 2). This distinction in
antibiotic treatment incidence change over the period between
younger and older patients appears to have been driven at least in
part by changing thresholds for intervention in younger patients,
where significantly fewer clinical symptoms (on average) were
associated with interventions in children less than 6 years of age
over time (Table 3). Although observed changes in IV antibiotic
treatment incidence coincided with an increased intensity of
chronic therapy use during the period [26], we have not demon-
strated a causal relationship between the two.
These data highlight inherent challenges in using antibiotic
treatment as a surrogate for clinical diagnosis of PEx. Although
such an approach may be valid in controlled randomized trials of
relatively short duration, clinician attitudes and practice patterns
have the potential to change (and in this case apparently did
change) over longer periods of observation. These data also
highlight the challenges in using retrospective analyses to “score”
clinical symptoms associated with PEx. The original Rabin study
identified clinical presentations most commonly associated with
PEx treatment: a clinical encounter in which a patient presented
with a Rabin score of 3 or 4 was highly likely to result in
antibiotic treatment for PEx [32]. However, Rabin et al. never
suggested that the converse was true: that antibiotic treatment for
PEx was highly likely to be associated with a Rabin score of 3 or
4. In fact, a large percentage of PEx resulting in antibiotic
treatments were associated with Rabin scores of 0 or 1, as we also
observed in this study. This distinction reflects the difficulty in
reducing the constellation of signs and symptoms that may lead to
a clinical diagnosis of PEx [5] to a manageable few for the
purposes of development of a clinical score.
There is a real evidence of a significant reduction in the
antibiotic treatment incidence for PEx between 1995 and 2005.
However, clinical practice patterns with respect to pulmonary sign
and symptom thresholds for antibiotic intervention, particularly in
the youngest CF patients, have evolved in parallel over the timeperiod, appearing to partially offset what might have been an even
greater reduction in treatment incidence. These results suggest that
epidemiologists and clinical trial designers should exercise caution
when using historical data or data averaged over extended periods
to draw conclusions with respect to antibiotic treatments for PEx.
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